US Supreme Court turns down Novartis bid to block launch of multiple sclerosis drug Gilenya generics
Novartis settled with some of the drugmakers it had sued, allowing for some Gilenya generics before a key patents 2027 expiration.
United States Justice John Roberts Aurobindo Pharma Ltd Us Court Drug Administration Us Supreme Court On
Source: medicaldialogues.in